AKRO:NSD-Akero Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 27.31

Change

+0.90 (+3.41)%

Market Cap

USD 0.92B

Volume

0.18M

Average Target Price

USD 62.43 (+128.59%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+10.32 (+6.89%)

USD59.96B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.19 (+0.55%)

USD55.89B 20.99 15.27
REGN Regeneron Pharmaceuticals, Inc

+4.12 (+0.86%)

USD51.11B 15.63 12.19
ALXN Alexion Pharmaceuticals, Inc

+1.56 (+1.01%)

USD33.80B 56.52 33.71
BNTX BioNTech SE

+2.96 (+2.28%)

USD31.31B -99,999.99 N/A
BGNE BeiGene, Ltd

+0.34 (+0.11%)

USD28.62B N/A N/A
SGEN Seagen Inc

+3.31 (+2.35%)

USD25.54B 41.81 34.88
RPRX Royalty Pharma plc

+0.69 (+1.67%)

USD25.15B 22.60 15.33
GMAB Genmab A/S

+0.02 (+0.06%)

USD22.68B 26.59 3.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AKRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.85% 58% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.85% 58% F 46% F
Trailing 12 Months  
Capital Gain 27.44% 48% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.44% 48% F 29% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 19.56% 55% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.56% 55% F 69% D+
Risk Return Profile  
Volatility (Standard Deviation) 27.54% 89% B+ 60% D-
Risk Adjusted Return 71.01% 92% A- 85% B
Market Capitalization 0.92B 69% D+ 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.18 47% F 79% C+
Price/Book Ratio 3.73 61% D- 45% F
Price / Cash Flow Ratio -12.97 66% D 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -40.89% 66% D 27% F
Return on Invested Capital -41.38% 59% F 20% F
Return on Assets -24.35% 53% F 16% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 9.28 15% F 6% F
Short Percent 15.04% 13% F 12% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector